U.S. pharma large copyright scrapped two experimental weight loss products past yr—a once-every day capsule, lotiglipron, due to elevated liver enzymes in addition to a twice-day-to-day tablet, danuglipron, as a result of potent side effects—but CEO Albert Bourla has explained the company is determined to “Participate in and win” while in t